CNSP - CIK 0001729427
CNS Pharmaceuticals, Inc. (CNSP) reported net income of -$15.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$15.85M | -6.7% |
| FY 2024 | -$14.86M | +21.2% |
| FY 2023 | -$18.85M | -23.4% |
| FY 2022 | -$15.27M | -5.4% |
| FY 2021 | -$14.50M | -53.3% |
| FY 2020 | -$9.46M | -143.9% |
| FY 2019 | -$3.88M | +47.5% |
| FY 2018 | -$7.39M | - |
CNS Pharmaceuticals, Inc. (CNSP) reported net income of -$15.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, CNS Pharmaceuticals, Inc.'s net income declined from -$7.39M to -$15.85M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.